Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3125-3132

  Torisu Itakura, Hitoe ^a   Lee, Jonathan H ^a   Scheri, Randall P ^a   Huynh, Young ^a   Ye, Xing ^a   Essner, Richard ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 13; LEPTIN; LYMPHOTOXIN BETA RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MICROMETASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA EXTRACTION; SENTINEL LYMPH NODE;

ANTIGENS, CD3; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-13; LEPTIN; LYMPH NODES; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-11; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 34250671119     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2645     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-8.
3. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991;214:627-36.
4. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24:S8-10.
5. Guo J, Wen DR, Huang RR, et al. Detection ofmultiple melanoma-associated markers in melanoma cell lines by RT in situ PCR. Exp Mol Pathol 2003;74:140-7.
6. Lee JH, Torisu-Itakura H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-12.
7. Molenkamp BG, van Leeuwen PA, van den Eertwegh AJ, et al. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. Immunobiology 2006;211:651-61.
8. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
9. Essner R, Bostick PJ, Glass EC, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery 2000;127:26-31.
10. Liu Y-Y, Giuliano AE, Cabot MC. Antisense transfection of glucosylceramide synthase modulates gene profiles in response to doxorubicin treatment in drug resistant human breast cancer cells. Breast Cancer Res Treat 2202;76:S141.
11. Miyashiro I, Kuo C, Huynh K, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001;47:505-12.
12. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
13. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-23.
14. Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 2000;85:182-8.
15. Giorgadze TA, Zhang PJ, Pasha T, et al. Lymphatic vessel density is significantly increased in melanoma. JCutan Pathol 2004;31:672-7.
16. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999;1:197-207.
17. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci 2003;995:151-61.
18. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 2005;167:1301-7.
19. + T cell reactivity in the sentinel lymph node of GM-CSF - treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 2006;12:2826-33.
20. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-70.
21. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-3.
22. + Th0, Th1 and Th2T cell clones and EBV-transformed B cells. Int Immunol 1995;7:1405-16.
23. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
24. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997;387:206-9.
25. Faggioni R, Jones-Carson J, Reed DA, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor α and IL-18. Proc Natl Acad Sci U S A 2000;97:2367-72.
26. Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI. Leptin inhibits the anti-CD3- driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukoc Biol 2002;72:330-8.
27. Murphy M, Walter BN, Pike-Nobile L, et al. Expression of the lymphotoxin h receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 1998;5:497-505.
28. Browning JL, French LE.Visualization of lymphotoxin-β and lymphotoxin-β receptor expression in mouse embryos. J Immunol 2002;168:5079-87.
29. Hehlgans T, Stoelcker B, Stopfer P, et al. Lymphotoxin-β receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res 2002;62:4034-40.
30. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13:455-81.
31. Woodward JK, Elshaw SR, Murray AK, et al. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1α and TGF-β. Invest Ophthalmol Vis Sci 2002;43:3144-52.
32. Kaufmann A, Gemsa D, Sprenger H. Differential desensitization of lipopolysaccharide-inducible chemokine gene expression in human monocytes and macrophages. Eur J Immunol 2000;30:1562-7.
33. + T cell-dendritic cell interaction. Nature 2006;440:890-5.
34. Hilton DJ, Hilton AA, Raicevic A, et al. Cloning of a murine IL-11 receptor α-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994;13:4765-75.
35. Cherel M, Sorel M, Lebeau B, et al. Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood 1995;86:2534-40.
36. Asada H, Kishida T, Hirai H, et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 2002;5:609-16.
37. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
38. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.